JAC Advance Access published online on January 16, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh068
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review
1 Hôpital Bichat
Claude Bernard, 75877 Paris Cedex 18;
* Corresponding author. E-mail: claudette.muller{at}bch.ap-hop-paris.fr.
Received 22 July 2003
; revised 3 November 2003
; accepted 13 November 2003
The potential efficacy of an antibacterial depends
not only on its spectrum of activity but also on its concentration
at the site of infection. The tissue kinetics of telithromycin--the
first ketolide antibacterial--are reviewed here. Telithromycin
accumulates rapidly in white blood cells, inflammatory fluid, and
cells and tissues of the upper and lower respiratory tract, with
mean concentrations above the MICs of key respiratory pathogens.
Tissue kinetics of telithromycin support facilitated delivery to
the site of infection, good efficacy against intracellular respiratory
pathogens and respiratory pathogens at extracellular sites in the
airways, and effectiveness in the treatment of upper and lower respiratory
tract infections (RTIs). The tissue kinetics profile of telithromycin,
together with its microbiological profile, makes it a promising
new antibacterial for the treatment of community-acquired RTIs.
Keywords: antibacterial, ketolide, telithromycin, tissue
kinetics
Tissue kinetics of telithromycin, the first ketolide
antibacterial
2 City Hospital Birmingham, Birmingham,
UK
3 Aventis, Romainville Cedex, France;
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. Lippert, S. Gbenado, C. Qiu, B. Lavin, and S. J. Kovacs The Bioequivalence of Telithromycin Administered Orally as Crushed Tablets Versus Tablets Swallowed Whole J. Clin. Pharmacol., September 1, 2005; 45(9): 1025 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bosnar, Z. Kelneric, V. Munic, V. Erakovic, and M. J. Parnham Cellular Uptake and Efflux of Azithromycin, Erythromycin, Clarithromycin, Telithromycin, and Cethromycin Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2372 - 2377. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Zhanel, C. Johanson, N. Laing, T. Hisanaga, A. Wierzbowski, and D. J. Hoban Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1943 - 1948. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kasbekar and P. S. Acharya Telithromycin: The first ketolide for the treatment of respiratory infections Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Kuehnel, C. Schurr, K. Lotter, and F. Kees Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis J. Antimicrob. Chemother., April 1, 2005; 55(4): 591 - 594. [Abstract] [Full Text] [PDF] |
||||



